5th SOHO Italy Annual Conference
Avatar

SOHO Italy 2023: How I Manage Waldenstrom’s Macroglobulinemia in the Era of Novel Agents

By 5th SOHO Italy Annual Conference FEATURING Steven Treon
By 5th SOHO Italy Annual Conference FEATURING Steven Treon
0 views
December 4, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Recommended

AUTOPLAY
24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou
15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

19:00
Indy Hematology Review

Waldenstrom’s Macroglobulinemia: Approaching the Newly Diagnosed and…

Feat. S. Treon
09:27
ASH 2022 Conference Coverage

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

Feat. M. McMullin
16:25
Northwestern Medicine Oncology and Hematology

Diagnosis and Goals of Therapy in PV

Feat. B. Stein
06:51
Insights from 2023 ASH Annual Meeting

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Feat. D. Tremblay
10:49
Monia Marchetti

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
10:06
ASCO 2022 Conference Coverage

ASCO 2022 Bendamustine Rituximab vs. Ibrutinib as Primary Therapy fo…

Feat. J. Abeykoon
08:19
ASH 2022 Conference Coverage

ASH 2022 Results From the Phase 1/2 BRUIN Study: Safety & Tolera…

Feat. N. Shah
31:51
Indy Hematology Review

Managing Newly Diagnosed MM in 2023

Feat. S. Usmani
03:42
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "BELLWAVE-003 - A Phase 2 Dose Escalation,…

Feat. G. Perini
11:11
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Ibrutinib and Venetoclax in Symptomatic, Tr…

Feat. J. Castillo
24:53
Indy Hematology Review

Emerging and Current Treatment of Amyloidosis and Waldenstrom’s Macr…

Feat. M. Gertz
20:39
Indy Hematology Review

Emerging and Current Treatment of Waldenstrom’s Macroglobulinemia

Feat. S. Treon
03:40
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Long-Term Safety With ≥12 Months of Pirto…

Feat. C. Coombs
08:34
ASH 2022 Conference Coverage

ASH 2022: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-C…

Feat. M. Shadman
06:54
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: CD20-Targeted CAR-T Therapy for BTKi-Refractory W…

Feat. M. Shadman